Literature DB >> 34495772

PrEP for key populations: results from the first PrEP demonstration project in the Democratic Republic of the Congo.

Julie Franks1, Chloe Teasdale1,2,3, Halli Olsen1, Chunhui Wang1, Nadine Mushimebele1, Richted Tenda Mazala1, Tania Tchissambou1, Faustin Malele Bazola1, Trista Bingham4, Gaston Djomand4, Elie Mukinda5, Raimi Ewetola5, Elaine Abrams1,2,6, William Reidy1,6.   

Abstract

Oral pre-exposure prophylaxis (PrEP) is recommended for persons at substantial risk for HIV, including female sex workers (FSW), men who have sex with men (MSM), people who inject drugs (PWID), and transgender women (TGW). We report on a PrEP demonstration project at seven clinics in the Democratic Republic of the Congo. Routinely collected data were abstracted to assess PrEP uptake, scheduled visit attendance, and self-reported adherence. Between February and May 2018, 469 eligible clients were offered daily oral PrEP; 75.1% accepted: 78.7% FSW, 20.5% MSM, and 0.9% TGW. Two percent also identified as PWID. Attendance was 64.5% at one-month visits; 82.1% at three-month visits; and among 47.7% of clients who initiated PrEP at least six months before data abstraction, 85.8% at six-month visits. Among 66.3% of clients with at least one adherence assessment, 39% self-reported low adherence. Results demonstrate the acceptability of PrEP delivered in healthcare settings serving FSW, MSM, PWID, and TGW.

Entities:  

Keywords:  Democratic Republic of Congo; HIV prevention; Pre-exposure prophylaxis; female sex workers; key populations; men who have sex with men; people who inject drugs

Mesh:

Substances:

Year:  2021        PMID: 34495772     DOI: 10.1080/09540121.2021.1969332

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  1 in total

1.  A comparison of attitudes and knowledge of pre-exposure prophylaxis (PrEP) between hospital and Key Population Led Health Service providers: Lessons for Thailand's Universal Health Coverage implementation.

Authors:  Ajaree Rayanakorn; Sineenart Chautrakarn; Kannikar Intawong; Chonlisa Chariyalertsak; Porntip Khemngern; Debra Olson; Suwat Chariyalertsak
Journal:  PLoS One       Date:  2022-05-12       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.